Adapted from DeMichele A, et al. 2019.1
Median follow-up was 24.4 and 23.1 months for PS-matched IBRANCE+ letrozole and letrozole alone, respectively.
Adapted from DeMichele A, et al. 2021.3
Although median OS was reached in the LET alone group, significant censoring in the OS analysis highlights the need for subsequent evaluation with longer follow-upAt the time of analysis, more patients had died in the placebo + LET group (n=182;
*OS was defined as time in months from start of IBRANCE plus letrozole or letrozole alone to death due to any cause recorded by Flatiron in the data extract. Date of death was derived from a recent mortality data set generated by combining multiple data sources and benchmarked against the National Death Index. If patients did not die, they were censored at the study cut-off date of May 31, 2019. †Propensity score matching (PSM) stabilised weight-adjusted numbers of patients at risk are shown.
CI = confidence interval; LET = letrozole; n = number of patients; NE = not estimable; NR = not reached; OS = overall survival; PLA = placebo; PFS = progression-free survival; PSM = propensity score matching; rw = real world..
*Race by Cohort interaction was the only subgroup variable-by-treatment cohort interaction that was significant (p=0.0102); †Boneonly disease was defined as metastatic disease in the bone only; ‡Visceral disease was defined as metastatic disease in the lung and/or liver; patients could have had other sites of metastases. No visceral disease was defined as no lung or liver metastases.
CI = confidence interval; LET = letrozole; n/N = number of patients; OS = overall survival: ; PLA = placebo.
Observational retrospective analyses are designed to evaluate associations among variables and cannot establish causality. Observational retrospective analyses are not intended for direct comparison with clinical trials.3,4
© 2021 Pfizer Pte Ltd. All rights reserved.
The information provided in this site is intended only for Health Care Professionals in Singapore. The products discussed herein may have different product labelling in different countries. Pfizer Corporation Singapore Limited is a subsidiary of Pfizer Inc, a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.